Efficacy of dacaltasvir and sofosbuvir combination therapy in chronic HCV population in private clinic set up.

Abstract

All- oral antiviral therapy for chronic hepatitis C is standard of care in 2018. Daclatasvir and Sofosbuvir combination therapy was approved in 2015 by EASL. Generics are also available since 2016. Objectives: We evaluated efficacy of Daclatasvir and Sofosbuvir based therapy in cirrhotic and non-cirrhotic patients. Study Design: Retrospective Observational Study. Setting: Athar Medical Center Muslim Town, Sargodha Road, Faisalabad. Period: One Year Dec 2017 to Dec 2018. Material & Methods: 151 patients were treated with Daclatasvir 60 mg daily and Sofosbuvir 400 mg daily combination therapy. Decompensated Cirrhotic patients were treated for 6 months along with ribavirin according to weight of patient. Treatment experienced patients were treated along with ribavirin. Naïve non-cirrhotic patients were treated for three months or 12 weeks. Primary end point was negative SVR 24 weeks after completing therapy. Results: Over all 151 patients were treated. 85 (56.29%) patients were male. 30(19.86%) patients were cirrhotics and remaining were non-cirrhotics. SVR was obtained in 149 patients. Treatment failure was seen in one cirrhotic and one non-cirrhotic patient. Conclusion: Daclatasvir and Sofosbuvir combination is highly effective in chronic hepatitis C patients in our population of Faisalabad division.